Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors
Chemical Biology & Drug Design · 2023-02 · 101 (2) · 326-339
DOI: 10.1111/cbdd.14111 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 05.12.2022. Verfasst von Xiaochang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Guangdong Provincial People's Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China. Hauptthemen laut MEDLINE: Pharmacophore, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
GSK‐3β is a member of the GSKs subfamily and plays a major role in the regulation of transcriptional elongation, which has attracted widespread attention as a therapeutic target for AD. In this study, by combining pharmacophore‐based virtual screening and kinase inhibition assays, we have successfully identified four small molecules that inhibit GSK‐3β activity at micromolar potency. These hit compounds showed drug‐like properties according to Lipinski's rule of five and ADMET. An inter‐complex interaction study showed that all hit compounds adapted well to the ATP pocket of the GSK‐3β protein. Among them, hits 2 and 4 displayed considerable inhibitory activities with IC 50 value of 0.74 ± 0.04 μM and 2.32 ± 0.84 μM respectively. Overall, the discovered GSK‐3β inhibitors act as new chemical leads to develop improved inhibitors that block the interaction of GSK‐3β, and the hybrid virtual screening strategy designed in this study provides an important reference for design and synthesis novel selective GSK‐3β inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Guangdong Provincial People's Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China.
- Department of Cardiology, Vascular Center, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Coronary, Guangzhou, China.
- Heart Disease Prevention, Guangdong Provincial People's Hospital, Guangzhou, China.
- Guangdong Academy of Medical Sciences, Guangzhou, China.
Zitieren
APA
Liu, X., Yu, J., Luo, Y., & Dong, H. (2023). Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors. Chemical Biology & Drug Design, 101(2), 326-339. https://doi.org/10.1111/cbdd.14111
Vancouver
Liu X, Yu J, Luo Y, Dong H. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors. Chemical Biology & Drug Design. 2023;101(2):326-339. doi:10.1111/cbdd.14111
BibTeX
@article{Liu2023,
author = {Liu, Xiaochang and Yu, Jiaxue and Luo, Yongyan and Dong, Haojian},
title = {Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK ‐3β inhibitors},
journal = {Chemical Biology & Drug Design},
year = {2023},
volume = {101},
number = {2},
pages = {326--339},
doi = {10.1111/cbdd.14111}
}
EUVIMED